Chronic endothelin A receptor blockade in lambs with increased pulmonary blood flow and pressure

Sohrab Fratz, Barbara Meyrick, Boaz Ovadia, Michael J. Johengen, Olaf Reinhartz, Anthony Azakie, Greg Ross, Robert Fitzgerald, Peter Oishi, John Hess, Stephen M. Black, Jeffrey R. Fineman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Endothelin receptor blockade is an emerging therapy for pulmonary hypertension. However, hemodynamic and structural effects and potential changes in endogenous nitric oxide (NO)-cGMP and endothelin-1 signaling of chronic endothelin A receptor blockade in pulmonary hypertension secondary to congenital heart disease are unknown. Therefore, the objectives of this study were to determine hemodynamic and structural effects and potential changes in endogenous NO-cGMP and endothelin-1 signaling of chronic endothelin A receptor blockade in a lamb model of increased pulmonary blood flow following in utero placement of an aortopulmonary shunt. Immediately after spontaneous birth, shunt lambs were treated lifelong with either an endothelin A receptor antagonist (PD-156707) or placebo. At 4 wk of age, PD-156707-treated shunt lambs (n = 6) had lower pulmonary vascular resistance and right atrial pressure than placebo-treated shunt lambs (n = 8, P < 0.05). Smooth muscle thickness or arterial number per unit area was not different between the two groups. However, the number of alveolar profiles per unit area was increased in the PD-156707-treated shunt lambs (190.7 ± 5.6 vs. 132.9 ± 10.0, P < 0.05). Plasma endothelin-1 and cGMP levels and lung NOS activity, cGMP, eNOS, preproendothelin-1, endothelin-converting enzyme-1, endothelin A, and endothelin B receptor protein levels were similar in both groups. We conclude that chronic endothelin A receptor blockade attenuates the progression of pulmonary hypertension and augments alveolar growth in lambs with increased pulmonary blood flow.

Original languageEnglish (US)
Pages (from-to)L592-L597
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume287
Issue number3 31-3
DOIs
StatePublished - Sep 1 2004

Fingerprint

Endothelin A Receptors
Endothelin-1
Pulmonary Hypertension
Blood Pressure
Lung
Nitric Oxide
Hemodynamics
Placebos
Endothelin B Receptors
Endothelin Receptors
Atrial Pressure
Endothelins
Vascular Resistance
Smooth Muscle
Heart Diseases
Parturition
Growth
PD 156707
Proteins
Therapeutics

Keywords

  • Congenital heart defect
  • Pulmonary heart disease

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology

Cite this

Chronic endothelin A receptor blockade in lambs with increased pulmonary blood flow and pressure. / Fratz, Sohrab; Meyrick, Barbara; Ovadia, Boaz; Johengen, Michael J.; Reinhartz, Olaf; Azakie, Anthony; Ross, Greg; Fitzgerald, Robert; Oishi, Peter; Hess, John; Black, Stephen M.; Fineman, Jeffrey R.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 287, No. 3 31-3, 01.09.2004, p. L592-L597.

Research output: Contribution to journalArticle

Fratz, S, Meyrick, B, Ovadia, B, Johengen, MJ, Reinhartz, O, Azakie, A, Ross, G, Fitzgerald, R, Oishi, P, Hess, J, Black, SM & Fineman, JR 2004, 'Chronic endothelin A receptor blockade in lambs with increased pulmonary blood flow and pressure', American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 287, no. 3 31-3, pp. L592-L597. https://doi.org/10.1152/ajplung.00093.2004
Fratz, Sohrab ; Meyrick, Barbara ; Ovadia, Boaz ; Johengen, Michael J. ; Reinhartz, Olaf ; Azakie, Anthony ; Ross, Greg ; Fitzgerald, Robert ; Oishi, Peter ; Hess, John ; Black, Stephen M. ; Fineman, Jeffrey R. / Chronic endothelin A receptor blockade in lambs with increased pulmonary blood flow and pressure. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2004 ; Vol. 287, No. 3 31-3. pp. L592-L597.
@article{6d31d872b69d4139bd833a78080966eb,
title = "Chronic endothelin A receptor blockade in lambs with increased pulmonary blood flow and pressure",
abstract = "Endothelin receptor blockade is an emerging therapy for pulmonary hypertension. However, hemodynamic and structural effects and potential changes in endogenous nitric oxide (NO)-cGMP and endothelin-1 signaling of chronic endothelin A receptor blockade in pulmonary hypertension secondary to congenital heart disease are unknown. Therefore, the objectives of this study were to determine hemodynamic and structural effects and potential changes in endogenous NO-cGMP and endothelin-1 signaling of chronic endothelin A receptor blockade in a lamb model of increased pulmonary blood flow following in utero placement of an aortopulmonary shunt. Immediately after spontaneous birth, shunt lambs were treated lifelong with either an endothelin A receptor antagonist (PD-156707) or placebo. At 4 wk of age, PD-156707-treated shunt lambs (n = 6) had lower pulmonary vascular resistance and right atrial pressure than placebo-treated shunt lambs (n = 8, P < 0.05). Smooth muscle thickness or arterial number per unit area was not different between the two groups. However, the number of alveolar profiles per unit area was increased in the PD-156707-treated shunt lambs (190.7 ± 5.6 vs. 132.9 ± 10.0, P < 0.05). Plasma endothelin-1 and cGMP levels and lung NOS activity, cGMP, eNOS, preproendothelin-1, endothelin-converting enzyme-1, endothelin A, and endothelin B receptor protein levels were similar in both groups. We conclude that chronic endothelin A receptor blockade attenuates the progression of pulmonary hypertension and augments alveolar growth in lambs with increased pulmonary blood flow.",
keywords = "Congenital heart defect, Pulmonary heart disease",
author = "Sohrab Fratz and Barbara Meyrick and Boaz Ovadia and Johengen, {Michael J.} and Olaf Reinhartz and Anthony Azakie and Greg Ross and Robert Fitzgerald and Peter Oishi and John Hess and Black, {Stephen M.} and Fineman, {Jeffrey R.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1152/ajplung.00093.2004",
language = "English (US)",
volume = "287",
pages = "L592--L597",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "3 31-3",

}

TY - JOUR

T1 - Chronic endothelin A receptor blockade in lambs with increased pulmonary blood flow and pressure

AU - Fratz, Sohrab

AU - Meyrick, Barbara

AU - Ovadia, Boaz

AU - Johengen, Michael J.

AU - Reinhartz, Olaf

AU - Azakie, Anthony

AU - Ross, Greg

AU - Fitzgerald, Robert

AU - Oishi, Peter

AU - Hess, John

AU - Black, Stephen M.

AU - Fineman, Jeffrey R.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Endothelin receptor blockade is an emerging therapy for pulmonary hypertension. However, hemodynamic and structural effects and potential changes in endogenous nitric oxide (NO)-cGMP and endothelin-1 signaling of chronic endothelin A receptor blockade in pulmonary hypertension secondary to congenital heart disease are unknown. Therefore, the objectives of this study were to determine hemodynamic and structural effects and potential changes in endogenous NO-cGMP and endothelin-1 signaling of chronic endothelin A receptor blockade in a lamb model of increased pulmonary blood flow following in utero placement of an aortopulmonary shunt. Immediately after spontaneous birth, shunt lambs were treated lifelong with either an endothelin A receptor antagonist (PD-156707) or placebo. At 4 wk of age, PD-156707-treated shunt lambs (n = 6) had lower pulmonary vascular resistance and right atrial pressure than placebo-treated shunt lambs (n = 8, P < 0.05). Smooth muscle thickness or arterial number per unit area was not different between the two groups. However, the number of alveolar profiles per unit area was increased in the PD-156707-treated shunt lambs (190.7 ± 5.6 vs. 132.9 ± 10.0, P < 0.05). Plasma endothelin-1 and cGMP levels and lung NOS activity, cGMP, eNOS, preproendothelin-1, endothelin-converting enzyme-1, endothelin A, and endothelin B receptor protein levels were similar in both groups. We conclude that chronic endothelin A receptor blockade attenuates the progression of pulmonary hypertension and augments alveolar growth in lambs with increased pulmonary blood flow.

AB - Endothelin receptor blockade is an emerging therapy for pulmonary hypertension. However, hemodynamic and structural effects and potential changes in endogenous nitric oxide (NO)-cGMP and endothelin-1 signaling of chronic endothelin A receptor blockade in pulmonary hypertension secondary to congenital heart disease are unknown. Therefore, the objectives of this study were to determine hemodynamic and structural effects and potential changes in endogenous NO-cGMP and endothelin-1 signaling of chronic endothelin A receptor blockade in a lamb model of increased pulmonary blood flow following in utero placement of an aortopulmonary shunt. Immediately after spontaneous birth, shunt lambs were treated lifelong with either an endothelin A receptor antagonist (PD-156707) or placebo. At 4 wk of age, PD-156707-treated shunt lambs (n = 6) had lower pulmonary vascular resistance and right atrial pressure than placebo-treated shunt lambs (n = 8, P < 0.05). Smooth muscle thickness or arterial number per unit area was not different between the two groups. However, the number of alveolar profiles per unit area was increased in the PD-156707-treated shunt lambs (190.7 ± 5.6 vs. 132.9 ± 10.0, P < 0.05). Plasma endothelin-1 and cGMP levels and lung NOS activity, cGMP, eNOS, preproendothelin-1, endothelin-converting enzyme-1, endothelin A, and endothelin B receptor protein levels were similar in both groups. We conclude that chronic endothelin A receptor blockade attenuates the progression of pulmonary hypertension and augments alveolar growth in lambs with increased pulmonary blood flow.

KW - Congenital heart defect

KW - Pulmonary heart disease

UR - http://www.scopus.com/inward/record.url?scp=4143065708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143065708&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00093.2004

DO - 10.1152/ajplung.00093.2004

M3 - Article

C2 - 15155268

AN - SCOPUS:4143065708

VL - 287

SP - L592-L597

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 3 31-3

ER -